| Literature DB >> 25221869 |
Parashar Thapa1, Rui-Yang Zhang1, Vinay Menon1, Jon-Paul Bingham2.
Abstract
The use of chemical ligation within the realm of peptide chemistry has opened various opportunities to expand the applications of peptides/proteins in biological sciences. Expansion and refinement of ligation chemistry has made it possible for the entry of peptides into the world of viable oral therapeutic drugs through peptide backbone cyclization. This progression has been a journey of chemical exploration and transition, leading to the dominance of native chemical ligation in the present advances of peptide/protein applications. Here we illustrate and explore the historical and current nature of peptide ligation, providing a clear indication to the possibilities and use of these novel methods to take peptides outside their typically defined boundaries.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25221869 PMCID: PMC6271921 DOI: 10.3390/molecules190914461
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Highlighting the advantages, disadvantages, and underlying mechanism of hydrazone, oxime, thiazolidine and thioester ligation.
| Technique | Advantages | Disadvantages | Ref. |
|---|---|---|---|
| Hydrazone Ligation | Greater hydrolytic stability Good water solubility Highly chemo-selective DMSO co-solvent accelerates reaction rate by 20× Bond is stable at neutral pH (5–7) | Reaction rate not affected by in pH Rate only mildly affected by temperature (37 °C) | [ |
| Oxime Ligation | Stable at room temp at pH 2–7 Fragments self-assemble under relatively mild conditions Reaction goes close to completion (~90%) Good yield Poly-oximes are easily purified and water soluble | Long reaction time (16–18 h) Basic pH leads to more side reactions | [ |
| Thiazolidine Ligation | Can create longer polypeptides (>50 residues) Good yield Retains Kd similar to native Acidic conditions prevents side reactions of aldehydes Ring formation is quick and complete (5–15 min) No protection groups Highly selective reaction | Heavy metal catalyst needed (Ag+) Highly acidic conditions (TFA) Possible reduction in Vmax | [ |
| Thioester Ligation | Ligation of N and C-terminal fragments occurs rapidly via SN2 reaction Ligation product was indefinitely stable at pH 4.3 (ligation conditions) Easily purified by RP-HPLC Ligation site can be replaced with any amino acid | HF is necessary for Boc deprotection Thioester bond is labile at higher pH, with hydrolysis occurring at ~7.5, leading to a half-life of about 2 h Must account for inversion of configuration that occurs with SN2 reactions | [ |
Scheme 1The mechanism of Native Chemical Ligation. R1 can be an Alkyl or an Aryl group.
Scheme 2Mechanism depicting the steps of Auxiliary Mediated Ligation (AML), a technique used to join two peptide fragments resulting in large peptide molecules [36].
Figure 1(a) Scheme showing sequential ligation strategy for joining peptide fragments together in order to produce a large peptide molecule [45]; (b) Scheme showing a strategy for ligating smaller fragments together in a convergent fashion in order to produce larger peptide molecules [45].
Scheme 3Mechanism showing the cyclization of a linear peptide. (a) Intramolecular nucleophilic attack results in a cyclic peptide joined by a thioester bond (b) S-N Acyl Shift produces the final cyclic molecule now joined by a native peptide bond.
Examples of the application of NCL to circumvent peptide size limitation. Cysteine residues used as ligation sites are in bold and larger font. γ = Gamma carboxyglutamic acid.
| Toxin/Peptide | Application | Sequence | Ref. |
|---|---|---|---|
| Human interleukin 8 (IL-8) | Chemokine, chemoattractants for leukocytes | SAKELRCQCIKTYSKPFHPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDPKEWVQRVVEKFLKRAENS | [ |
| Human group II secretory phospholipase A2 (sPLA2) | Hydrolysis of the fatty acid side chain ester bond | NLVNFHRMIKLTTGKEAALSYGFYGCHCGVGGRGSPKDATDRCCVTHDCCYKRLEKRGCGTKFLSYKFSNSGSRITCAKQDSCRSQLCECDKAAATCFARNKTTYNKKYQYYSNKHCRGSTPRC | [ |
| Microprotein S | Anticoagulant cofactor activity | NSLLγγTKQGNLγRγCIγγLCNKγγARγVFγNDPγTDYFYPKYLGCLRSFQTGLFTAARQSTNAYPDLRSCVNAIPDQCSPLPCNEDGYMSCKDGKASFTCTCKPGWQG EKCEFD | [ |
| Barnase (Lys49-Cys49) | Microbial ribonuclease | AQVINTFDGVADYLQTYHKLPNDYITKSEAQALGWVASKGNLADVAPGCSIGGDIFSNREGKLPGKSGRTWREADINYTSGFRNSDRILYSSDWLIYKTTDHYQTFTKIR | [ |
Examples of the application of NCL to synthesize challenging peptide sequences. Cysteine residues used as ligation sites are in bold and larger font.
| Toxin/Peptide | Application | Sequence | Ref. |
|---|---|---|---|
| Ec-MscL | Mechanosensitive ion channel | MSIIKEFREFAMRGNVVDLAVGVIIGAAFGKIVSSLVADIIMPPLGLLIGGIDFKCFAVTLRDAQGDIPAVVMHYGVFIQNVFDFLIVAFAIFMAIKLINKLCRKKEEPAAAPAPTKEEVLLTEIRDLLKEQNNRS | [ |
| IbTx V16A/D19-Cys-4-MeOBzl | Binding to BK Ca2+-activated K+ channel (KCa1.1) | ZFTDVDCSVSKECWSACKX2LFGVDRGKCMGKKCRCYQ (X2 = Cys-4-MeOBzl) | [ |
| Snow Flea Antifreeze Protein (sfAFP) | Inhibition of Ice Crystal Formation | CLGADGAHGVNGCPGTAGAAGSVGGPGCDGGHGGNGGNGNPGCAGGVGGAGGASGGTGVGGRGGKGGSGTPKGADGAPGAP | [ |
| KcsA (Pro2-Ala2, Gln58-Ala58, Thr61-Ser61, Arg64-Asp64) | Potassium Channel | MAPMLSGLLARLVKLLLGRHGSALHWRAAGAATVLLVIVLLAGSYLAVLAERGAPGAALISYPDALWWSVETACTVGYGDLYPVTLWGRLVAVVVMVAGITSFGLVTAALATWFVGREQERRGK | [ |
Figure 2The figure demonstrates the application of Native Chemical Ligation in conducting an Alanine Scanning to study structure-activity relationships. The equal sign (=) designates a thioester functionality.
Examples of the applications of NCL to synthesize glycopeptides and glycoproteins. Cysteine residues used as ligation sites are in bold and larger font. Glycosylation sites are shown with underlining residues.
| Toxin/Peptide | Application | Sequence | Ref. |
|---|---|---|---|
| Diptericin ε (Cys25,Glu29,Glu45) | Antibacterial glycopeptide | DEKPKLILP | [ |
| Lymphotactin (Lptn) | Chemoattractant (for T- cell and natural killer cell) | VGSEVSDKRTCVSLTTQRLPVSRIKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVVRSMDRKSNTRNNMIQ | [ |
| RNase B Fragment | Cleavage of | MKSR | [ |
| CCL7 (MCP-3) | Monocyte specific chemotactic protein-3 | QPVGI | [ |